14. Pierre Fenaux, Ghulam J Mufti,Eva Hellstrom-Lindberh,et al. Efficacy of azacitidine compared with that of conventional care regimens in the treatment of higher-risk myelodysplastic syndromes: a randomised, open-label, phase III study.Lancet Oncol,2009,10: 223-232 15.Lyons RM,Cosgriff TM...
prognostic score, which is based on some of the features of your disease. This can help determine if you have lower-risk MDS, which may mean that you can live for years before you need treatment, or higher-risk MDS, which may mean a shorter life expectancy and more aggressive treatment....
life expectancyRinged Sideroblastfunctional failurerefractory anemiairon chelationprecursorsReactive Oxygen SpeciesThe issue whether iron overload (10) contributes to the patho-physiology of myelodysplastic syndrome (MDS) and therefore requires treatment, is still controversial. There is no question that ...
Steensma DP, Baer MR, Slack JL, et al. Multicenter study of decitabine administered daily for 5 days every 4 weeks to adults with myelodysplastic syndromes: the alternative dosing for outpatient treatment (ADOPT) trial. J Clin Oncol, 2009, 27:3842-3848. Blum W. How much? How frequent? How...
Like in the years before, the majority of contributions dealt with preclinical aspects. In addition to that, several interesting clinical studies regarding diagnosis and treatment were presented. 展开 关键词: Myelodysplastic syndrome ASH 2013 Highlights ...
However, this study emphasized that alloreactivity is the main therapeutic principle that contributes to exceeding tolerable conditioning intensity in MDS treatment. 2.2. Melphalan comparison with busulfan To increase the likelihood of sustainable remission, melphalan was introduced to RIC for the treatment...
Matrix metalloproteinase 1(MMP1), which was downregulated in MDS-MSCs, was identified as an inhibitory factor of MDS cell proliferation, given that treatment with an MMP1 inhibitor or knock-down of MMP1 in normal MSCs resulted in increased MDS cell proliferation. Further investigations indicated ...
Patients were eligible for enrollment if they have an ECOG performance status of 0-1, adequate organ function, a life expectancy of at least 3 months, and had not received major surgery within 30 days of the first study treatment. Patients were not eligible for participation if they had recei...
Given our observation of a correlation of iron overload with the HCT-CI, it may be speculated that iron chelation can result in improvement of comorbidities, which may affect patient outcome, especially after intensive treatment, such as PBSCT. Because the intensity of transplantation conditioning ...
As an exception, lenalidomide treatment was forced to remain in the multivariate models to evaluate the magnitude of risk associated with lenalidomide in the presence of the other covariates. In addition to assessing the proportional hazards assumption for Cox modeling,16 the robustness of these ...